Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

Author(s):
Franken, M.G.; Leeneman, B.; Jochems, A.; Schouwenburg, M.G.; Aarts, M.J.B.; Akkooi, A.C.J. van; Berkmortel, F.W.P.J. van den; Eertwegh, A.J.M. van den; Groot, J.W.B. de; Hoeven, K.J.M. van der; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.; Kruit, W.H.J.; Louwman, M.W.J.; Piersma, D.; Rijn, R.S. van; Suijkerbuijk, K.P.M.; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M.; Zeijl, M. van; Haanen, J.B.A.G.; Uyl-de Groot, C.A.
Published
2018
Publication type
Article / Letter to editor
advanced cutaneous melanomacolitishealthcare costsimmune-related adverse eventsipilimumab
Date issued
2018-07-31
Language
English
Is part of
Anti-Cancer Drugs (2018), Vol. 29, no. 6, p. 579-588
hdl
1887/96178
doi
10.1097/CAD.0000000000000628